Headquartered in Watertown, MA Fiscal year ends December NASDAQ: KYMR kymeratx.com
Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation (TPD). It develops oral small molecule degrader medicines for immunological diseases, aimed at disease targets and pathways that conventional therapeutics cannot reach.
Its wholly owned clinical pipeline includes:
- **KT-621:** A first-in-class, once-daily oral STAT6 degrader for Type 2 inflammatory diseases. It is in Phase 2b trials in atopic dermatitis (BROADEN2) and eosinophilic asthma (BREADTH). Potential further indications include COPD, EoE, CRSwNP, CSU, prurigo nodularis and bullous pemphigoid.
- **KT-579:** A first-in-class oral IRF5 degrader that has completed a Phase 1 healthy volunteer trial. It is moving into the LUMORA Phase 1b trial in systemic lupus erythematosus, with potential in IBD, Sjögren's and rheumatoid arthritis.
Kymera also earns collaboration economics through partnerships:
- **Sanofi:** Leads development, regulatory and commercial efforts for KT-485/SAR447971, a second-generation oral IRAK4 degrader in Phase 1.
- **Gilead Sciences:** Holds an exclusive license to KT-200, an oral CDK2 molecular glue degrader for breast cancer and other solid tumors, now in IND-enabling studies.
The company aims to deliver at least one new development candidate per year from its discovery engine. It reported [USD:1645883000] in cash, cash equivalents and marketable securities as of September 30, 2026, with runway into 2029. Updated
KT-579 showed at least 90% median IRF5 degradation in Phase 1 with safety comparable to placebo, which is why zero collaboration revenue and a wider loss missing expectations barely register here. Cash funds operations into 2029, leaving year-end KT-621 atopic dermatitis topline data as the event that sets the price.
Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy stocks.
Pre-Market Stock Futures: Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower. This news comes after a bounce-back Tuesday…
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in…
Kodiak Sciences, Medline, and W.R. Berkley have seen some huge insider purchases, and there were some other notable insider purchases as well..
Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.
Pre-Market Stock Futures: The futures are trading modestly higher as Thanksgiving Eve has finally arrived. After a slow start on Tuesday, all the major indices began to rally by noon and finished…
Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation (TPD). It develops oral small molecule degrader medicines for immunological diseases, aimed at disease targets and pathways that conventional therapeutics cannot reach.
The Wall Street consensus 12-month price target for KYMR is $144.57.
